DaVita Inc. ($DVA) Stock Forecast: Up 9.2% Today

What is DaVita Inc.?

DaVita (NYSE: DVA) is seeing a significant uptrend in the stock market today.

Why is DaVita Inc. going up?

DVA stock is up 9.2% on Feb 4, 2026 19:41

• Company's price target was increased to $190 from $186 by UBS, noting strong 2026 guidance with anticipated growth in operating income and EPS, as well as benefits from the Elara Caring investment.
• Partnership with Elara Caring presents a novel approach to kidney and home care services, potentially broadening in-home health options for dialysis patients and promoting more integrated care models.
• Exceeding expectations, DaVita reported impressive fourth-quarter results with revenue hitting $3.62 billion and adjusted profit per share at $3.40, driving a substantial stock surge.
• Exceptional 2026 adjusted earnings per share forecast of $14.30, surpassing previous analyst estimates, has increased investor confidence in DaVita's future outlook.

DVA Price Chart

DVA Technical Analysis

DVA News

DaVita stock price target raised to $190 from $186 at UBS on growth outlook

UBS has raised its price target for DaVita (NYSE:DVA) to $190 from $186, maintaining a Buy rating, based on the company's strong 2026 guidance. DaVita projects adjusted operating income growth of 3% and adjusted EPS growth of 33%, the latter influenced by share buybacks and the resolution of prior joint venture losses. The company also anticipates positive contributions from its upcoming Elara Caring investment.

https://m.investing.com/news/analyst-ratings/davita-stock-price-target-raised-to-190-from-186-at-ubs-on-growth-outlook-93CH-4485588?ampMode=1

DaVita, Elara deal could signal new take on kidney, home care

DaVita's deal with Elara Caring suggests a new direction for kidney and home care services, aiming to expand in-home health options for dialysis patients. This collaboration could lead to more integrated care models, providing greater access to home-based treatment. The article highlights this development as a significant step in post-acute care.

https://www.modernhealthcare.com/post-acute-care/mh-davita-elara-caring-home-care/

Earnings To Watch: Encompass Health (EHC) Reports Q4 Results Tomorrow

Encompass Health (EHC) is scheduled to report its Q4 results this Thursday after market hours. Analysts anticipate a 9.6% year-on-year revenue growth to $1.54 billion and adjusted earnings of $1.30 per share. Investors are watching closely, especially given the stock's recent 12.4% dip compared to the healthcare sector's average 1.7% decline.

https://finviz.com/news/298586/earnings-to-watch-encompass-health-ehc-reports-q4-results-tomorrow

Why Is DaVita (DVA) Stock Rocketing Higher Today

DaVita Inc. (NYSE:DVA) shares surged by 25.3% after the dialysis provider reported fourth-quarter results that exceeded Wall Street's expectations and provided a strong earnings forecast for 2026. The company's revenue reached $3.62 billion and adjusted profit hit $3.40 per share, both beating consensus estimates. DaVita also projected a robust 2026 adjusted earnings per share with a midpoint of $14.30, significantly surpassing prior analyst expectations and boosting investor confidence.

https://www.theglobeandmail.com/investing/markets/stocks/DVA/pressreleases/37387311/why-is-davita-dva-stock-rocketing-higher-today/

Research Alert: CFRA Maintains Hold View On Shares Of Davita Inc.

MT Newswires reported that CFRA has maintained its "Hold" rating on shares of Davita Inc. (DVA). The article also briefly mentioned Unity Software's (U.US) fourth-quarter financial results, noting a 35% revenue increase year-over-year to $609 million, exceeding estimates, but also reporting a quarterly loss of 66 cents per share. Investors are directed to log in or create an account to view the full news.

https://news.futunn.com/en/post/68378479/research-alert-cfra-maintains-hold-view-on-shares-of-davita

Trending Today

XRP ($XRP) Crypto Forecast: Down 5.3% Today

Beyond Meat Inc. ($BYND) Stock Forecast: Down 5.2% Today

Digital Turbine, Inc. ($APPS) Stock Forecast: Down 5.4% Today

Cencora Inc. ($COR) Stock Forecast: Down 9.2% Today

Chubb Limited ($CB) Stock Forecast: Up 5.1% Today

Aurora Cannabis Inc. ($ACB) Stock Forecast: Down 7.4% Today

Martin Marietta Materials Inc. ($MLM) Stock Forecast: Up 2.0% Today

Amcor plc ($AMCR) Stock Forecast: Up 7.8% Today

Take-Two Interactive Software Inc. ($TTWO) Stock Forecast: Down 5.0% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Down 5.6% Today

DaVita Inc. Price History

09.00.2026 - DVA Stock was down 1.8%

• DaVita HealthCare Partners stock hit a 52-week low at $112.53, reflecting a significant 24.81% decline over the past year.
• Despite trading below its Fair Value and having a strong free cash flow yield, the stock has been under pressure due to missing Q3 2025 earnings expectations, reporting an EPS of $2.51 against a projected $3.23.
• The company's aggressive share buyback program and the addition of a new board member, Gregory J. Moore, from Tolion Health AI, might indicate strategic efforts to navigate through the challenging market conditions.
• The extension of the Updated Product Purchase Agreement with Rockwell Medical with a price increase could potentially provide a slight boost to DaVita's revenue stream, but the overall market sentiment remains bearish for now.

30.09.2025 - DVA Stock was down 5.2%

• DaVita HealthCare (DVA) reported Q3 earnings below estimates, showing a negative surprise in earnings but a slight positive surprise in revenue.
• Despite efforts to enhance performance through technology upgrades and cost control, challenges like high missed treatments and low volume growth may have negatively impacted the stock.
• Investor concerns about the company's ability to address these operational issues and achieve sustainable growth may have contributed to today's bearish stock movement.

14.00.2026 - DVA Stock was down 5.8%

• On January 13, DaVita Inc. (DVA) experienced a notable decline of 3.83%, reaching an intraday low. Several factors could have contributed to this movement:
• The stock performed poorly compared to its industry peers, marking its third consecutive day of losses as major market indices like the S&P 500 and Dow Jones Industrial Average also saw declines.
• DaVita's stock reached a 52-week low, signaling a 33.52% drop over the past year. Despite analysts deeming it undervalued, the recent earnings disappointments and industry headwinds have fueled negative market sentiment.
• Analysts hold a bullish long-term perspective, setting price targets as high as $186. However, current market dynamics may be swayed by concerns surrounding financial performance and broader sectoral challenges.

13.00.2026 - DVA Stock was down 5.0%

• DaVita's stock plummeted to a 52-week low, reflecting a negative investor sentiment.
• Despite analysts deeming the stock undervalued and displaying strong financial indicators like a low P/E ratio and high free cash flow yield, a recent earnings disappointment likely contributed to the decline in stock value.
• The renewal of the supply agreement with Rockwell Medical, coupled with a price hike, could have sparked worries about DaVita's cost efficiency and future profitability, affecting investor trust.
• DaVita's shift towards a comprehensive kidney care platform, while holding potential long-term benefits, may be clouded by uncertainties over its implementation and short-term financial consequences, further fueling the negative market sentiment.

31.09.2025 - DVA Stock was down 6.2%

• Post its Q3 earnings release, DaVita's stock witnessed a downward trend.
• The company showed revenue growth, but its earnings fell short of expectations, resulting in a decline in stock prices.
• Concerns about financial performance arise from narrower margins and earnings below estimates.
• Investors seemed dissatisfied with the earnings miss, overshadowing positive elements such as revenue growth and cost management endeavors.

04.01.2026 - DVA Stock was up 9.2%

• Company's price target was increased to $190 from $186 by UBS, noting strong 2026 guidance with anticipated growth in operating income and EPS, as well as benefits from the Elara Caring investment.
• Partnership with Elara Caring presents a novel approach to kidney and home care services, potentially broadening in-home health options for dialysis patients and promoting more integrated care models.
• Exceeding expectations, DaVita reported impressive fourth-quarter results with revenue hitting $3.62 billion and adjusted profit per share at $3.40, driving a substantial stock surge.
• Exceptional 2026 adjusted earnings per share forecast of $14.30, surpassing previous analyst estimates, has increased investor confidence in DaVita's future outlook.

10.11.2025 - DVA Stock was up 2.2%

• Despite DaVita Inc. falling short of recent EPS expectations and receiving cautious ratings from analysts, various institutional investors have notably increased their stakes in the company, including L2 Asset Management LLC, Norges Bank, Arrowstreet Capital Limited Partnership, Quantbot Technologies LP, and Edgestream Partners L.P.
• The stock's positive movement could be attributed to these institutional investments, indicating confidence in DaVita's long-term prospects despite recent performance challenges.
• Market attention appears to be shifting towards DaVita's future potential, as demonstrated by increased institutional ownership, rather than solely focusing on recent financial results and analyst outlooks.
• Anticipation surrounding the company's FY2025 guidance, which analysts are predicting DaVita will meet, may have also fueled positive sentiment and stock movement.

03.01.2026 - DVA Stock was up 23.2%

• DaVita delivered impressive Q4 2025 earnings, exceeding projections with an EPS of $3.40 and offering a positive outlook for 2026. This robust financial performance likely influenced the stock's upward trajectory.
• Institutional investors, such as Mirae Asset Global Investments Co. Ltd., notably enlarged their position in DaVita, demonstrating their faith in the company's future prospects.
• While concerns exist regarding slowing revenue growth and decreasing margins, DaVita's targeted efforts to enhance patient care and profitability appear to have garnered favor among investors, propelling the stock upwards.
• The prevailing positive sentiment in the market, as evidenced by the increase in S&P 500 futures, may have also contributed to the further rise in DaVita's stock value.

03.01.2026 - DVA Stock was up 20.2%

• DaVita's robust Q4 performance and positive 2026 guidance bolstered investor confidence, leading to a 25% increase in its stock value.
• The 14.2% decline in short interest suggests a change in sentiment toward the company after its solid financial showing.
• Enhanced margins, driven by increased revenue per treatment and strategic acquisitions, contributed to the favorable market response and stock price appreciation.
• DaVita's commitment to enhancing patient care, reducing mortality rates, and pursuing future growth through strategic moves, as highlighted in the earnings call, further reinforced investor confidence in the company's future prospects.

06.00.2026 - DVA Stock was down 2.5%

• The bearish movement in DaVita's stock today can be attributed to a cautious outlook.
• The extension of the supply agreement with Rockwell Medical, coupled with a price adjustment for products, might have raised concerns among investors about potential cost implications for DaVita.
• Despite recent success in cost controls and market optimism, DaVita faces challenges from U.S. healthcare policies and reimbursement risks, which could have contributed to the negative market sentiment.
• The ownership structure of DaVita, with Berkshire Hathaway as a major shareholder reducing its stake, alongside insider trading activities indicating a cautious approach, may have added to the downward pressure on the stock.

07.00.2026 - DVA Stock was down 3.8%

• DaVita HealthCare Partners stock hit a 52-week low due to a 24.81% decline over the past year, exacerbated by a recent earnings miss in Q3 2025.
• Despite trading below its Fair Value and having a strong free cash flow yield, the company's challenges in the market and the earnings disappointment contributed to the bearish movement.
• The extension of the supply agreement with Rockwell Medical, including a price adjustment, may have also impacted investor sentiment, adding to the overall negative outlook for DaVita HealthCare Partners.
• The addition of a former Microsoft and Google executive to Tolion Health AI's Board could signal potential strategic shifts in the industry, but it did not provide enough positive momentum to offset the stock's downward trend.

04.01.2026 - DVA Stock was up 6.6%

• Collaborating with Elara Caring to expand home-based care options for dialysis patients has sparked investor optimism and signaled a shift towards integrated care models and increased access to in-home treatment.
• The company's strong Q4 results, exceeding revenue and earnings expectations, coupled with a positive forecast for 2026, have increased investor confidence and boosted the stock price.
• DaVita's share repurchase and optimistic guidance for the upcoming year demonstrate confidence in its strategic direction and potential for sustained growth, contributing to the current bullish market trend.